Anti-cancer immunotherapy: Phase I/II started

Quantum began an open-label, U.S. Phase I/II trial to evaluate 3 doses of the vaccine immunotherapy given every 2-3 weeks in 25 patients who have not responded to traditional therapies. The immunizing...